GA NCORP

TRIALS & PROVIDERS

Menu

NCORP Trials

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Status
Completed
Cancer Type
Gynecologic Cancers
Ovarian Cancer
Primary Peritoneal Cancer
Unknown Primary
Trial Phase
Phase III
Eligibility
18 Years and older, Female
Study Type
Treatment
NCD ID
NCT04729608
Protocol IDs
AVB500-OC-004 (primary)
GOG-3059
NCI-2021-05984
AXLerate-OC
ENGOT OV66
Study Sponsor
Aravive, Inc.
NCI Full Details
http://clinicaltrials.gov/show/NCT04729608

Summary

This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of
batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination
with PAC in patients with platinum resistant recurrent ovarian cancer.
CALL EMAIL

Copyright © 2015, Georgia NCI Community Oncology Research Program. All Rights Reserved.
Powered by GeorgiaCancerInfo.org
Website Design & Development by Peachtree Solutions.